title: Significant elevation of serum levels of eotaxin-3/CCL26, but not of eotaxin-2/CCL24, in patients with atopic dermatitis: serum eotaxin-3/CCL26 levels reflect the disease activity of atopic dermatitis.
abstract: Atopic dermatitis (AD) is a chronic and relapsing inflammatory skin disease characterized by the predominant infiltration of T cells, eosinophils and macrophages in lesional skin. Recently, eotaxin-2/CCL24 and eotaxin-3/CCL26 were identified as CC chemokines that signal exclusively via the CCR3 receptor and have eosinophil-selective chemoattractant activity, as does eotaxin/CCL11. We previously reported that serum levels of thymus and activation-regulated chemokine (TARC)/CCL17 and macrophage-derived chemokine (MDC)/CCL22 were correlated with the severity of AD. In this report, we investigated the participation of eotaxin-2/CCL24 and eotaxin-3/CCL26 in AD, first measuring the serum levels of eotaxin-2/CCL24 and eotaxin-3/CCL26 in 30 patients with AD, 20 patients with psoriasis vulgaris and 20 healthy controls. The serum levels of eotaxin-3/CCL26 (but not eotaxin-2/CCL24) were significantly higher in patients with AD than in either healthy controls or patients with psoriasis vulgaris; furthermore, the eotaxin-3/CCL26 levels in patients with moderate and severe AD were significantly higher than eotaxin-3/CCL26 levels in patients with mild AD. The serum eotaxin-3/CCL26 levels tended to decrease after treatment, but there was no significant difference between groups. Moreover, the serum eotaxin-3/CCL26 levels were significantly correlated with the serum TARC/CCL17 and MDC/CCL22 levels, eosinophil numbers in peripheral blood and the scoring AD (SCORAD) index. Our study strongly suggests that serum levels of eotaxin-3/CCL26, but not of eotaxin-2/CCL24, have a notable correlation with disease activity of AD and that eotaxin-3/CCL26, as well as TARC/CCL17 and MDC/CCL22, may be involved in the pathogenesis of AD.
authors: Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan. kagamis-tky@umin.ac.jp
authors: S
authors: S
authors: Kagami
authors: T
authors: T
authors: Kakinuma
authors: H
authors: H
authors: Saeki
authors: Y
authors: Y
authors: Tsunemi
authors: H
authors: H
authors: Fujita
authors: K
authors: K
authors: Nakamura
authors: T
authors: T
authors: Takekoshi
authors: M
authors: M
authors: Kishimoto
authors: H
authors: H
authors: Mitsui
authors: H
authors: H
authors: Torii
authors: M
authors: M
authors: Komine
authors: A
authors: A
authors: Asahina
authors: K
authors: K
authors: Tamaki
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D054423:Chemokine CCL24; D000075906:Chemokine CCL26; D019742:Chemokines, CC / Q000097:blood*; D003876:Dermatitis, Atopic / Q000097:blood* / Q000188:drug therapy; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D011565:Psoriasis / Q000097:blood; D012720:Severity of Illness Index
chemical_list: D015415:Biomarkers; C515484:CCL24 protein, human; C120429:CCL26 protein, human; D054423:Chemokine CCL24; D000075906:Chemokine CCL26; D019742:Chemokines, CC